tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Inflammation D007249 119 associated lipids
Influenza, Human D007251 11 associated lipids
Insulin Resistance D007333 99 associated lipids
Intertrigo D007402 1 associated lipids
Intestinal Atresia D007409 3 associated lipids
Intestinal Fistula D007412 1 associated lipids
Intestinal Pseudo-Obstruction D007418 5 associated lipids
Intussusception D007443 1 associated lipids
Ischemia D007511 18 associated lipids
Kaposi Varicelliform Eruption D007617 1 associated lipids
Kartagener Syndrome D007619 2 associated lipids
Keloid D007627 12 associated lipids
Kidney Diseases D007674 29 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Kidney Tubular Necrosis, Acute D007683 3 associated lipids
Vulvar Lichen Sclerosus D007724 1 associated lipids
Labyrinthitis D007762 2 associated lipids
Leg Injuries D007869 2 associated lipids
Legionellosis D007876 3 associated lipids
Lentigo D007911 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Ramos-Cebrián M et al. Conversion from tacrolimus to cyclosporine could improve control of posttransplant diabetes mellitus after renal transplantation. 2007 Transplant. Proc. pmid:17889154
López Lago AM et al. Evolution of hepatorenal syndrome after orthotopic liver transplantation: comparative analysis with patients who developed acute renal failure in the early postoperative period of liver transplantation. 2007 Transplant. Proc. pmid:17889176
Loinaz C et al. A single-centre experience with cyclosporine microemulsion versus tacrolimus in 100 randomized liver transplant recipients: midterm efficacy and safety. 2001 Nov-Dec Transplant. Proc. pmid:11750472
Tolba RH et al. Conversion to Neoral for tacrolimus-related adverse effects in liver transplant recipients and improvement in quality of life. 2001 Nov-Dec Transplant. Proc. pmid:11750475
Uchida K et al. Decreasing pancreatic toxicity of tacrolimus by dosage reduction. 1998 Transplant. Proc. pmid:9636518
Rostaing L et al. Early posttransplantation renal hemodynamics in FK 506-treated kidney recipients with or without prior induction therapy. 1998 Transplant. Proc. pmid:9636519
García Meseguer C et al. Anti-HLA antibodies posttransplantation in children: do we know what it means? 2009 Jul-Aug Transplant. Proc. pmid:19715846
Crespo M et al. De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels. 2009 Jul-Aug Transplant. Proc. pmid:19715848
Tang J et al. Cytokine Profile in Calcineurin Inhibitor-Induced Chronic Nephrotoxicity in Chinese Liver Transplant Recipients. 2016 Transplant. Proc. pmid:27788813
Asselin I et al. Polymerase chain reaction-based assay to assess the success of myoblast transplantation in mdx mice. 1994 Transplant. Proc. pmid:7527970
Kinoshita I et al. Immunosuppression with FK 506 insures good success of myoblast transplantation in MDX mice. 1994 Transplant. Proc. pmid:7527978
Azhderian EM et al. Nucleus associated FK 506 binding proteins with potential relevance to FK 506 immunosuppression. 1993 Transplant. Proc. pmid:7679834
Wong KM et al. Tacrolimus versus cyclosporine as primary prophylactic therapy after cadaveric renal transplant: two-year survival study. 2000 Transplant. Proc. pmid:11119907
Porayko MK et al. Nephrotoxicity of FK 506 and cyclosporine when used as primary immunosuppression in liver transplant recipients. 1993 Transplant. Proc. pmid:7679835
Kawauchi M et al. Plasma level of FK 506 in newborn goats and infant baboons. 1991 Transplant. Proc. pmid:1721267
Iwasaki K et al. Pharmacokinetic study of FK 506 in the rat. 1991 Transplant. Proc. pmid:1721268
Andersson J et al. FK 506 and cyclosporine inhibit antigen- or mitogen-induced monokine and lymphokine production in vitro. 1992 Transplant. Proc. pmid:1371621
Morozumi K et al. A comparative study of morphological characteristics of renal injuries of tacrolimus (FK506) and cyclosporin (CyA) in renal allografts: are the morphologic characteristics of FK506 and CyA nephrotoxicity similar? 1996 Transplant. Proc. pmid:8623232
Takada S et al. HGF prevents tacrolimus (FK 506)-induced nephrotoxicity in SHR rats. 1996 Transplant. Proc. pmid:8623236
Imventarza O et al. Renal transplantation in baboons under FK 506. 1990 Transplant. Proc. pmid:1689903
Monden M et al. A potent immunosuppressive effect of FK 506 in orthotopic liver transplantation in primates. 1990 Transplant. Proc. pmid:1689904
Ciancio G et al. Efficacy and safety of daclizumab induction for primary kidney transplant recipients in combination with tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression. 2003 Transplant. Proc. pmid:12644172
Cofan F et al. Oxidation of low-density lipoproteins in renal transplant recipients treated with tacrolimus. 2002 Transplant. Proc. pmid:11959335
Steinmueller T et al. Effect of CsA versus FK 506 on insulin sensitivity and insulin response using a modeling technique. 1998 Transplant. Proc. pmid:9636589
Miura S et al. The beneficial effects of FK 506 on living-related renal transplantation in presensitized recipients. 1999 Transplant. Proc. pmid:10455940
Braun F et al. An ex vivo model to study the intestinal biotransformation of immunosuppressives. 2000 Transplant. Proc. pmid:11120282
Ringe B et al. Replacement of corticosteroids by mycophenolate mofetil in liver graft recipients on initial tacrolimus immunosuppression. 2000 Transplant. Proc. pmid:11120285
Vanrenterghem Y Vascular rejection with tacrolimus and potential long-term graft outcome. 1999 Transplant. Proc. pmid:10576054
Alloway RR et al. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience. 1996 Transplant. Proc. pmid:8623494
Dumont FJ et al. Up-regulation of gene expression by FK 506. 1991 Transplant. Proc. pmid:1721300
Jain A et al. FK 506 in small bowel transplant recipients: pharmacokinetics and dosing. 1994 Transplant. Proc. pmid:7518149
Borrows R et al. Tacrolimus monitoring in renal transplantation: a comparison between high-performance liquid chromatography and immunoassay. 2005 Transplant. Proc. pmid:15919448
Takara T et al. Intraportal donor-specific transfusion given 24 hours before small bowel transplantation with cyclosporine and FK 506. 1994 Transplant. Proc. pmid:7518150
Koefoed-Nielsen PB et al. Comparison of the temporal profile of calcineurin inhibition by cyclosporine and tacrolimus in renal transplant patients. 2005 Transplant. Proc. pmid:15919449
Iwahori T et al. Pharmacokinetic differences between morning and evening administration of cyclosporine and tacrolimus therapy. 2005 Transplant. Proc. pmid:15919450
Jain A et al. Intravenous, oral pharmacokinetics, and oral dosing of FK 506 in small bowel transplant patients. 1992 Transplant. Proc. pmid:1376518
Watanabe K et al. Factors influencing long-term operational tolerance in dogs treated with fractionated lymphoid irradiation, donor bone marrow cell infusion and FK506. 1995 Transplant. Proc. pmid:7533389
Kitamura T et al. Severe hemolytic anemia related to production of cold agglutinins following living donor liver transplantation: a case report. 2003 Transplant. Proc. pmid:12591458
Borg AJ and Kumagai M FK 506 and xenogeneic human anti-porcine cellular reactivity. 1991 Transplant. Proc. pmid:1721332
Lladó L et al. Prospective study of a tacrolimus-based quadruple immunosuppressive regimen: evaluation of safety and efficacy. 2002 Transplant. Proc. pmid:12176468
Fleck PR et al. Tacrolimus use in kidney-pancreas recipients is associated with less acute renal dysfunction than cyclosporine. 1998 Transplant. Proc. pmid:9865299
Foroncewicz B et al. Safety and efficacy of steroid-free immunosuppression with tacrolimus and daclizumab in liver transplant recipients: 6-year follow-up in a single center. 2009 Transplant. Proc. pmid:19857686
Niel OR et al. Long-term glomerular filtration rate in liver allograft recipients according to the type of calcineurin inhibitors. 2009 Transplant. Proc. pmid:19857743
Regazzi MB et al. Pharmacokinetics of FK506 and mycophenolic acid in experimental and clinical intestinal transplantation. 1997 Transplant. Proc. pmid:9142302
Hansen LJ et al. Early pharmacokinetic profiles of enteral tacrolimus after multivisceral transplantation. 1997 Transplant. Proc. pmid:9142303
Oltean M et al. FK506 donor pretreatment improves intestinal graft microcirculation and morphology by concurrent inhibition of early NF-kappaB activation and augmented HSP72 synthesis. 2005 Transplant. Proc. pmid:15919508
Kobayashi M et al. Posttransplant donor-specific T-lymphocytotoxic antibody in liver transplant patients with a positive crossmatch. 1992 Transplant. Proc. pmid:1281570
Lemster B et al. Cytokine gene expression in murine lymphocytes activated in the presence of FK 506, bredinin, mycophenolic acid, or brequinar sodium. 1992 Transplant. Proc. pmid:1281576
Ciftci HS et al. Effect of MDR1 polymorphisms on the blood concentrations of tacrolimus in Turkish renal transplant patients. 2013 Transplant. Proc. pmid:23622581
Japanese study of FK 506 on kidney transplantation: results of an early phase II study. Japanese FK 506 Study Group. 1991 Transplant. Proc. pmid:1721363
van Hoek B et al. Recurrence of ductopenic rejection in liver allografts after retransplantation for vanishing bile duct syndrome. 1991 Transplant. Proc. pmid:1703343
Jensen CW et al. Pediatric renal transplantation under FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721364
McCauley J et al. The question of FK 506 nephrotoxicity after liver transplantation. 1991 Transplant. Proc. pmid:1703344
Solà R et al. Tacrolimus in induction immunosuppressive treatment in renal transplantation: comparison with cyclosporine. 2003 Transplant. Proc. pmid:12962763
Ciancio G et al. Effect of daclizumab, tacrolimus and mycophenolate mofetil in racial minority first renal transplant recipients. 2002 Transplant. Proc. pmid:12176508
Yamauchi M et al. Effects of FK506 on rat thymic microenvironment in thymocyte maturation, proliferation, and mobilization. 1998 Transplant. Proc. pmid:9838578
Mueller AR et al. Is the use of marginal liver grafts justified? 1999 Feb-Mar Transplant. Proc. pmid:10083160
Takeuchi H et al. Evidence of different pharmacokinetics between cyclosporine and tacrolimus in renal transplant recipients: why cyclosporine is monitored by C2 level and tacrolimus by trough level. 2008 Transplant. Proc. pmid:18790203
Zipperle S et al. Impaired T-cell IL-10 secretion and CD4 helper function in liver transplant patients treated with tacrolimus. 1997 Feb-Mar Transplant. Proc. pmid:9123208
Sato K et al. Pancreaticoduodenal allotransplantation with cyclosporine and FK506. 1989 Transplant. Proc. pmid:2468212
Freise CE et al. Similar clinical presentation of neurotoxicity following FK 506 and cyclosporine in a liver transplant recipient. 1991 Transplant. Proc. pmid:1721397
Toraishi T et al. Falsely abnormally elevated blood trough concentration of tacrolimus measured by antibody-conjugated magnetic immunoassay in a renal transplant recipient: a case report. 2012 Transplant. Proc. pmid:22310597
Lee PC et al. Cyclosporine or tacrolimus: which is the better partner for myfortic or cellcept? 2012 Transplant. Proc. pmid:22310598
Klupp J et al. New approach in drug development: whole blood pharmacodynamic assays reflect biological activities of tacrolimus. 2001 Transplant. Proc. pmid:11377491
Pozzetto U et al. Effects of immunosuppressive regimens on plasma levels of transforming growth factor-beta 1 in renal transplant recipients. 2002 Transplant. Proc. pmid:12176558
McGrath JS and Shehata M The effect of differing immunosuppressive regimes on the functional and morphologic changes in a rat renal allograft model of chronic rejection. 2001 Transplant. Proc. pmid:11377499
Koefoed-Nielsen PB and Jørgensen KA Alterations in calcineurin phosphatase activity in tacrolimus-treated renal transplant patients. 2002 Transplant. Proc. pmid:12176559
Utsugi R et al. Tolerance across a two-haplotype, fully MHC-mismatched barrier induced in miniature swine renal allografts treated with a 12-day course of tacrolimus. 2001 Feb-Mar Transplant. Proc. pmid:11266727
Gasser M et al. Putative regulatory function of alloreactive Th2 cells in tolerant recipients after small bowel transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11266759
Schorlemmer HU et al. Coadministration of malononitrilamides and tacrolimus induces tolerance in a rat skin allograft model. 1999 Feb-Mar Transplant. Proc. pmid:10083529
Jiang H et al. Inhibition of IL-10 by FK 506 may be responsible for overcoming ongoing allograft rejection in the rat. 1999 Feb-Mar Transplant. Proc. pmid:10083538
Kahan BD High variability of drug exposure: a biopharmaceutic risk factor for chronic rejection. 1998 Transplant. Proc. pmid:9723224
Sheng H et al. Ocular complications of heart transplantation in a Chinese population. 2008 Transplant. Proc. pmid:19100445
Shi Y et al. Comparison of Mizoribine and Mycophenolate Mofetil With a Tacrolimus-Based Immunosuppressive Regimen in Living-Donor Kidney Transplantation Recipients: A Retrospective Study in China. Transplant. Proc. pmid:28104150
Lauro A et al. Liver transplantation for familial amyloid polyneuropathy non-VAL30MET variants: are cardiac complications influenced by prophylactic pacing and immunosuppressive weaning? 2005 Transplant. Proc. pmid:15964382
Takeda Y et al. Effect of FK 506 on the survival of rat small bowel allografts. 1991 Transplant. Proc. pmid:1721426
Kokado Y et al. Hypertension in renal transplant recipients and its effect on long-term renal allograft survival. 1996 Transplant. Proc. pmid:8658802
Fukuzawa M et al. Effect of donor-specific transfusion and FK 506 on small intestine allotransplantation. 1991 Transplant. Proc. pmid:1721427
Park KM et al. Bone loss after orthotopic liver transplantation: FK 506 versus cyclosporine. 1996 Transplant. Proc. pmid:8658863
Tamura K et al. A highly sensitive method to assay FK-506 levels in plasma. 1987 Transplant. Proc. pmid:2445069
Venkataramanan R et al. Biopharmaceutical aspects of FK-506. 1987 Transplant. Proc. pmid:2445070
MacDonald AS Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas, and kidney transplantation. 2003 Transplant. Proc. pmid:12742497
Sindhi R et al. Pharmacodynamics of sirolimus in transplanted children receiving tacrolimus. 2002 Transplant. Proc. pmid:12176644
Rayhill SC et al. A cyclosporine-based immunosuppressive regimen may be better than tacrolimus for long-term liver allograft survival in recipients transplanted for hepatitis C. 2006 Transplant. Proc. pmid:17175350
Chakrabarti P et al. Outcome after steroid withdrawal in adult renal transplant patients receiving tacrolimus-based immunosuppression. 2001 Feb-Mar Transplant. Proc. pmid:11267274
Xu M et al. FTY720 compares with FK 506 as rescue therapy in rat heterotopic cardiac transplantation. 1998 Transplant. Proc. pmid:9723447
Maroun T et al. Rejection therapy with tacrolimus in renal transplantation: preliminary results of a collaborative multicenter study in 45 patients. Groupe Cooperatif de Transplantation D'ile de France (GCIF). 1998 Transplant. Proc. pmid:9745576
Alvarez-Elías AC et al. CYP3A5 Genotype and Time to Reach Tacrolimus Therapeutic Levels in Renal Transplant Children. 2016 Transplant. Proc. pmid:27110018
Reiner J et al. After Intestinal Transplantation Kidney Function Is Impaired by Downregulation of Epithelial Ion Transporters in the Ileum. 2016 Transplant. Proc. pmid:27109987
Fung JJ and Starzl TE FK 506 in solid organ transplantation. 1994 Transplant. Proc. pmid:7524226
McCauley J et al. FK 506 in the management of transplant-related nephrotic syndrome and steroid-resistant nephrotic syndrome. 1991 Transplant. Proc. pmid:1721459
Carrieri G et al. Effect of FK 506 in the prophylaxis of autoimmune glomerulonephritis in NZB/WF1 mice. 1991 Transplant. Proc. pmid:1721460
Griffin AD et al. FK 506 in canine renal transplantation. 1992 Transplant. Proc. pmid:1384209
Garcia CD et al. Pediatric renal transplantation under tacrolimus or cyclosporine immunosuppression and basiliximab induction. 2002 Transplant. Proc. pmid:12431513
Lo A et al. Limited benefits of induction with monoclonal antibody to interleukin-2 receptor in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous kidney-pancreas transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267477
Uemoto S et al. Safety and efficacy of once-daily modified-release tacrolimus in liver transplant recipients: a multicenter postmarketing surveillance in Japan. 2014 Transplant. Proc. pmid:24767340
Owen ER et al. Peripheral nerve regeneration in human hand transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267484
Stempfle HU et al. Rapid trabecular bone loss after cardiac transplantation using FK506 (tacrolimus)-based immunosuppression. 1998 Transplant. Proc. pmid:9636459
García-Bello JA et al. Effect of Immunosuppressive Therapy on Cardiovascular Risk Factor Prevalence in Kidney-Transplanted Children: Comparative Study. 2016 Transplant. Proc. pmid:27110020
Ericzon BG et al. Effect of FK 506 on glucose metabolism in the cynomolgus monkey: studies in pancreatic transplant recipients and nontransplanted animals. 1991 Transplant. Proc. pmid:1703695